Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic Biosciences (NASDAQ:XBIO) released a Virtual Investor segment featuring Dr. Reid Bissonnette discussing recent preclinical data presented at the SITC 39th Annual Meeting. The data shows that DNase I significantly improves the effectiveness of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma. This is particularly significant as MSS/MMRp CRC affects approximately 85% of colorectal cancer patients, a group that has historically shown response to immune checkpoint blockade treatments.
Xenetic Biosciences (NASDAQ:XBIO) ha rilasciato un segmento per investitori virtuali con il Dott. Reid Bissonnette che discute i recenti dati preclinici presentati al 39° Congresso Annuale SITC. I dati mostrano che DNase I migliora significativamente l'efficacia del blocco del checkpoint immunitario anti-CTLA-4 in modelli preclinici di carcinoma colorettale microsatellite stabile/proficiente nella riparazione degli errori (MSS/MMRp). Questo è particolarmente significativo poiché il CRC MSS/MMRp colpisce circa l'85% dei pazienti con cancro colorettale, un gruppo che storicamente ha mostrato risposta ai trattamenti con i blocchi del checkpoint immunitario.
Xenetic Biosciences (NASDAQ:XBIO) lanzó un segmento para inversores virtuales en el que el Dr. Reid Bissonnette discute los recientes datos preclínicos presentados en el 39° Congreso Anual de SITC. Los datos muestran que DNase I mejora significativamente la efectividad del bloqueo del checkpoint inmunitario anti-CTLA-4 en modelos preclínicos de carcinoma colorrectal con microsatélites estables/proficiente en reparación de errores (MSS/MMRp). Esto es particularmente significativo ya que el CRC MSS/MMRp afecta aproximadamente al 85% de los pacientes con cáncer colorrectal, un grupo que históricamente ha mostrado respuesta a tratamientos de bloqueo de checkpoint inmunitario.
Xenetic Biosciences (NASDAQ:XBIO)는 SITC 제39회 연례회의에서 발표된 최근의 전임상 데이터를 논의하는 Dr. Reid Bissonnette가 출연하는 가상 투자자 세그먼트를 공개했습니다. 데이터는 DNase I이 면역 체크포인트 차단제인 anti-CTLA-4의 효과를 전임상 모델인 마이크로새틀라이트 안정성/잘못된 수리 능력(MSS/MMRp) 대장암에서 상당히 개선한다는 것을 보여줍니다. 이는 MSS/MMRp CRC가 대장암 환자의 약 85%에 영향을 미치는 만큼 특히 중요하며, 이 집단은 전통적으로 면역 체크포인트 차단 치료에 반응을 보여왔습니다.
Xenetic Biosciences (NASDAQ:XBIO) a publié un segment d'investisseurs virtuels mettant en vedette le Dr Reid Bissonnette discutant des récentes données précliniques présentées lors de la 39ème Réunion Annuelle SITC. Les données montrent que DNase I améliore significativement l'efficacité du blocage du point de contrôle immunitaire anti-CTLA-4 dans des modèles précliniques de carcinome colorectal à microsatellites stables/proficients en réparation des erreurs (MSS/MMRp). Cela est particulièrement significatif car le CRC MSS/MMRp affecte environ 85% des patients atteints de cancer colorectal, un groupe qui a historiquement montré une réponse aux traitements par blocage des points de contrôle immunitaires.
Xenetic Biosciences (NASDAQ:XBIO) veröffentlichte ein virtuelles Investoren-Segment mit Dr. Reid Bissonnette, der über die jüngsten präklinischen Daten spricht, die auf dem 39. Jahrestreffen der SITC präsentiert wurden. Die Daten zeigen, dass DNase I die Wirksamkeit der anti-CTLA-4 Immun-Checkpoint-Blockade signifikant verbessert in präklinischen Modellen von mikrosatellitär stabile/mismatch-repair-fähiger (MSS/MMRp) kolorektalem Karzinom. Dies ist besonders bedeutend, da MSS/MMRp CRC etwa 85% der kolorektalen Krebspatienten betrifft, eine Gruppe, die historisch gesehen auf Behandlungen mit Immun-Checkpoint-Blockaden reagiert hat.
- Positive preclinical data showing DNase I significantly improves treatment efficacy
- Potential treatment solution for 85% of colorectal cancer patients (MSS/MMRp CRC) who currently have treatment options
- None.
Insights
The preclinical data presentation for DNase I combined with anti-CTLA-4 therapy is scientifically interesting but lacks sufficient detail about specific efficacy metrics or statistical significance. While targeting MSS/MMRp colorectal cancer represents a large market opportunity (
The company's
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Watch the "What This Means" video here
FRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment.
As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent positive data demonstrating DNase I significantly improves efficacy of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma (CRC) which was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. MSS/MMRp CRC represents approximately
The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications, ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors, our strategic focus on exploratory investigator-initiated studies with institutional partners, including leveraging institutional partnerships to drive our development strategy, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, our expectations regarding preclinical data generated to date, our focus on building a growing body of data and further developing our pipeline to build value in the near and long term, our plans regarding presentations of the results of preclinical data, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program towards Phase 1 clinical development as an adjunctive therapy for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What did Xenetic Biosciences (XBIO) present at the SITC 39th Annual Meeting?
What percentage of colorectal cancer patients could benefit from Xenetic Biosciences' (XBIO) treatment approach?
What is the significance of Xenetic Biosciences' (XBIO) DNase I treatment findings?
